Pricing updated 2019-07-17. Prices are subject to change without notice.
XL335 is an orally bioavailable and potent agonist of the farnesoid X receptor (FXR) with an EC50 value of 4 nM in CV-1 cells transfected with human FXR.1 It is selective for FXR over a panel of 15 nuclear receptors at concentrations up to 10 μM. XL335 induces expression of mouse intestinal bile acid binding protein (IBABP), human bile salt excretory pump (BSEP), and small heterodimer partner (SHP) genes in reporter gene assays. It also induces a 20-, 13-, and 2-fold increase in mRNA expression for IBABP, BSEP, and SHP, respectively, at a concentration of 1 μM. XL335 (3 mg/kg) reduces plasma cholesterol and triglycerides by 39 and 50%, respectively, and decreases the area of pre-atherosclerotic lesions in LDLR-/- mice fed a Western diet. It also decreases hepatic fibrosis in a mouse model of non-alcoholic steatohepatitis.2
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
Flatt, B., Martin, R., Wang, T.L., et al. Discovery of XL335 (WAY-
Zhang, S., Wang, J., Liu, Q., et al. Farnesoid X receptor agonist WAY-